{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:02:40Z","timestamp":1790798560806,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08079-0","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:45:23Z","timestamp":1790797523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability"],"prefix":"10.1007","volume":"219","author":[{"given":"Shivahamy","family":"Maheswaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin S.","family":"Dedeoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Niemierko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel O.","family":"Abelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Rieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Vidula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif W.","family":"Ellisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Wander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle J.","family":"Medford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"8","key":"8079_CR1","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41379-022-01017-7","volume":"35","author":"A Stradella","year":"2022","unstructured":"Stradella A, Gargallo P, Cejuela M et al (2022) Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma. Mod Pathol 35(8):1066\u20131074. https:\/\/doi.org\/10.1038\/s41379-022-01017-7","journal-title":"Mod Pathol"},{"issue":"4","key":"8079_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/CEJ.0000000000000794","volume":"32","author":"G Corso","year":"2023","unstructured":"Corso G, Criscitiello C, Nicosia L et al (2023) Metaplastic breast cancer: an all-round multidisciplinary consensus. Eur J Cancer Prev 32(4):348\u2013363. https:\/\/doi.org\/10.1097\/CEJ.0000000000000794","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"8079_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-011-1359-8","volume":"126","author":"SY Bae","year":"2011","unstructured":"Bae SY, Lee SK, Koo MY et al (2011) The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 126(2):471\u2013478. https:\/\/doi.org\/10.1007\/s10549-011-1359-8","journal-title":"Breast Cancer Res Treat"},{"key":"8079_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-0780-8","volume":"120","author":"SY Jung","year":"2010","unstructured":"Jung SY et al (2010) Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120:627\u2013637","journal-title":"Breast Cancer Res Treat"},{"key":"8079_CR5","doi-asserted-by":"publisher","first-page":"102885","DOI":"10.1016\/j.ctrv.2025.102885","volume":"133","author":"P Dai","year":"2025","unstructured":"Dai P, Song T, Liu J et al (2025) Therapeutic strategies and landscape of metaplastic breast cancer. Cancer Treat Rev 133:102885. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102885","journal-title":"Cancer Treat Rev"},{"key":"8079_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41523-021-00302-z","volume":"7","author":"W Wong","year":"2021","unstructured":"Wong W, Brogi E, Reis-Filho JS et al (2021) Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. npj Breast Cancer 7:96. https:\/\/doi.org\/10.1038\/s41523-021-00302-z","journal-title":"npj Breast Cancer"},{"key":"8079_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7819-11-129","volume":"11","author":"Y Song","year":"2013","unstructured":"Song Y, Liu X, Zhang G et al (2013) Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 11:129 Published 2013 Jun 6. https:\/\/doi.org\/10.1186\/1477-7819-11-129","journal-title":"World J Surg Oncol"},{"key":"8079_CR8","doi-asserted-by":"publisher","unstructured":"Dong S, Fang Y, Syed S (2023) A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan. Curr Probl Cancer Case Rep 10;100239. https:\/\/doi.org\/10.1016\/j.cpccr.2023.100239","DOI":"10.1016\/j.cpccr.2023.100239"},{"key":"8079_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.29011\/2574-7754.101579","volume":"9","author":"AN Rodrigues","year":"2024","unstructured":"Rodrigues AN, Pereira DJ, Arenhardt MP, Giannecchini GV (2024) Case Report on Complete Response to Treatment of Metastatic Metaplastic Breast Cancer with Sacituzumab Govitecan. Ann Case Rep 9:1579. https:\/\/doi.org\/10.29011\/2574-7754.101579","journal-title":"Ann Case Rep"},{"issue":"1","key":"8079_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-025-07875-4","volume":"215","author":"J \u017bubrowska","year":"2025","unstructured":"\u017bubrowska J, Pieni\u0105\u017cek M, Polakiewicz-Gilowska A et al (2025) Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study. Breast Cancer Res Treat 215(1):35. https:\/\/doi.org\/10.1007\/s10549-025-07875-4","journal-title":"Breast Cancer Res Treat"},{"key":"8079_CR11","doi-asserted-by":"publisher","unstructured":"Spring LM et al (2021) Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. The Oncologist 26(10):827\u2013834. https:\/\/doi.org\/10.1002\/onco.13878","DOI":"10.1002\/onco.13878"},{"issue":"16","key":"8079_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"issue":"19","key":"8079_CR13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C et al (2025) Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med 393(19):1912\u20131925. https:\/\/doi.org\/10.1056\/NEJMoa2511734","journal-title":"N Engl J Med"},{"key":"8079_CR14","doi-asserted-by":"publisher","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K et al (2026) Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med 394(4):354\u2013366. https:\/\/doi.org\/10.1056\/NEJMoa2508959","DOI":"10.1056\/NEJMoa2508959"},{"issue":"1","key":"8079_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"issue":"25","key":"8079_CR16","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 384(25):2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"issue":"8","key":"8079_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 379(8):753\u2013763. https:\/\/doi.org\/10.1056\/NEJMoa1802905","journal-title":"N Engl J Med"},{"issue":"3","key":"8079_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW et al (2022) Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387(3):217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"issue":"1","key":"8079_CR19","doi-asserted-by":"publisher","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","volume":"10","author":"R Cristescu","year":"2022","unstructured":"Cristescu R, Aurora-Garg D, Albright A et al (2022) Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer 10(1):e003091. https:\/\/doi.org\/10.1136\/jitc-2021-003091","journal-title":"J Immunother Cancer"},{"issue":"13","key":"8079_CR20","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","volume":"23","author":"TM Cardillo","year":"2017","unstructured":"Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM (2017) Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1\/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res 23(13):3405\u20133415. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2401","journal-title":"Clin Cancer Res"},{"key":"8079_CR21","doi-asserted-by":"publisher","first-page":"e2100456","DOI":"10.1200\/PO.21.00456","volume":"6","author":"TA Yap","year":"2022","unstructured":"Yap TA, Hamilton E, Bauer T et al (2022) Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol 6:e2100456. https:\/\/doi.org\/10.1200\/PO.21.00456","journal-title":"JCO Precis Oncol"},{"key":"8079_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.2024.42.16_suppl.1102","volume":"42","author":"Rachel Occhiogrosso Abelman","year":"2024","unstructured":"Rachel Occhiogrosso Abelman (2024) Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study. J Clin Oncol 42:1102\u20131102. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1102","journal-title":"J Clin Oncol"},{"issue":"14","key":"8079_CR23","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Sun S, Thimmiah N et al (2024) Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clin Cancer Res 30(14):2917\u20132924. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0428","journal-title":"Clin Cancer Res"},{"key":"8079_CR24","doi-asserted-by":"publisher","unstructured":"Guo AG-GZ, Xiao S, Hoog J, Cynthia X (June 2025) Abstract P4-03-23: Preclinical investigation for the mechanisms of action of PARP inhibition in combination with trastuzumab deruxtecan (T-DXd) in triple negative breast cancer (TNBC). Clin Cancer Res 15(12 Suppl). https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-P4-03-23","DOI":"10.1158\/1557-3265.SABCS24-P4-03-23"},{"key":"8079_CR25","doi-asserted-by":"publisher","first-page":"156075","DOI":"10.1016\/j.prp.2025.156075","volume":"272","author":"M Rejili","year":"2025","unstructured":"Rejili M (2025) Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy. Pathol Res Pract 272:156075. https:\/\/doi.org\/10.1016\/j.prp.2025.156075","journal-title":"Pathol Res Pract"},{"issue":"9","key":"8079_CR26","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K et al (2021) Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 32(9):1148\u20131156. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08079-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:45:23Z","timestamp":1790797523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08079-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8079"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08079-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consent waived, IRB-approved.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mass General Brigham Institutional Review Board.","order":2,"name":"Ethics","label":"Institutional review board","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM: SM reports no conflict of interest with the content of the herein manuscript. ASD: ASD reports no conflict of interest with the content of the herein manuscript. AN: AN reports no conflict of interest with the content of the herein manuscript. ROA: Consultant for Precede Biosciences, Inc; Medspoke; MDOutlook RJ: Consultant for Alexion OR: OR reports no conflict of interest with the content of the herein manuscript. JH: JH reports no conflict of interest with the content of the herein manuscript. NV: Research funding to institution (MGH): Merck, Daehwa, Pfizer, Radius, Novartis, Stemline, Ellipses Advisory board participation: AbbVie, OncoSec, TerSera, Gilead, Aadi, Novartis, Daiichi, Pfizer LMS: Consultant\/advisory board: Novartis, Daiichi Pharma, Astra Zeneca, Eli Lilly, Precede, Seagen, Pfizer Institutional research support: Merck, Genentech, Gilead, Eli Lilly, Astra Zeneca LWE: Consulting\/Advisory Board: Astra Zeneca, Stemline, Kisoji, Atavistik, Gilead. Research Support: Sanofi, Eisa SJI: Consulting\/Advisory Board: Veracyte. Institutional Research: Genentech, AstraZeneca, Merck SAW: Consulting\/Advisory Board: Foundation Medicine, Veracyte, Hologic, Eli Lilly, Biovica, Pfizer\/Arvinas, Puma Biotechnology, Novartis, AstraZeneca, Genentech, RegorTherapeutics, Stemline\/Menarini, Gilead. Education\/Speaking: Eli Lilly, Guardant Health, 2ndMD. Institutional Research Support: Genentech, Eli Lilly, Pfizer\/Arvinas, Nuvation Bio, Regor Therapeutics, Sermonix, Puma Biotechnology, Stemline\/Menarini, Phoenix Molecular Designs AB: Consultant: Pfizer, Novartis, Merck, Genentech, AstraZeneca\/Daiichi, Alyssum, Menarini, Gilead, Eli Lilly. Support to institution: Pfizer, Novartis, Merck, Genentech, AstraZeneca\/Daiichi, Onkure, Menarini, Gilead, Eli Lilly. AJM: Dr. Medford has served as an advisor\/consultant for AstraZeneca, Asuragen, Edgewood Oncology, Guardant Health, Illumina, Myriad Genetics, Natera, Novartis, Neogenomics, Precede Biosciences, SAGA Diagnostics, Reversing Early Recurrence, and Science for America, outside the submitted work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26"}}